Recruiting studies: Group 3 Pulmonary Hypertension

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
Phase 3 · 92 location(s) · Tenax Therapeutics, Inc. · NCT07288398 A Trial of "APL-9796'' in Adults With Pulmonary Hypertension
Phase 2 · 6 location(s) · Apollo Therapeutics Ltd · NCT06846554 A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
Phase 3 · 16 location(s) · Liquidia Technologies, Inc. · NCT07285655 DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease
Phase N/A · 67 location(s) · United Therapeutics · NCT06388421 Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD (Windward)
Phase 2 · 9 location(s) · Foresee Pharmaceuticals Co., Ltd. · NCT06475781 Pulmonary Hypertension SOLAR
Phase 2 · 1 location(s) · Bastiaan Driehuys · NCT04778046 Exploration of Metabolome in Patients With Interstitial Lung Disease and Pulmonary Hypertension With or Without Specific
Phase N/A · 1 location(s) · Hospices Civils de Lyon · NCT07254338 A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants
Phase 3 · 2 location(s) · Insmed Incorporated · NCT07481981 Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension
Phase 3 · 109 location(s) · Insmed Incorporated · NCT07179380

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.